ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2998

Microchimerism Is Present in Systemic Sclerosis Lung and Includes CD31-Positive Cells

Coline GENTIL1, Julie Randolph-Habecker2, David. K. Madtes3,4, Min FANG5, Hilary S. Gammill6, Corinne L. Fligner7, McGarry, A. Houghton3,8 and J. Lee Nelson9,10, 1Clinical Division, Fred Hutchinson Cancer Research Center, SEATTLE, WA, 2Histopathology, Fred Hutchinson Cancer Research Center, SEATTLE, WA, 3Clinical Research, Fred Hutchinson Cancer Research Center, SEATTLE, WA, 4University of Washington, SEATTLE, WA, 5Cytogenetics, Seattle Cancer Care Alliance, SEATTLE, WA, 6Obstetrics and Gynecology, University of Washington, Seattle, WA, 7Pathology, University of Washington, SEATTLE, WA, 8Pulmonary medicine, University of Washington, SEATTLE, WA, 9Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 10University of Washington, Seattle, WA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Microchimerism and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Microchimerism (Mc), harboring a small number of cells (or DNA) that originated in a different individual, occurs commonly due to bi-directional maternal-fetal exchange during pregnancy and long-term persistence decades later. Mc has been implicated in some autoimmune diseases, especially systemic sclerosis (SSc), but any role in pathogenesis remains unclear. We sought to identify and characterize Mc at the site of disease pathology in SSc lung. 

Patients and Methods:

SSc lung specimens were obtained from autopsy. Of 9 patients, 7 had diffuse and 2 limited SSc; 6 were female, 3 male.  SSc onset age ranged from 25 to 56 (mean 45.6) and disease duration 1 to 8 years (mean 3.1). Causes of death were primarily pulmonary (interstitial fibrosis, hemorrhage), however 3 patients had cancer (1 lung, 2 breast) and cause of death was unclear for 1 patient. 3 had undergone autologous hematopoietic cell transplants and 2 cord blood transplants. For comparison, healthy tissue from surgical lung cancer resections are being studied, to date 2 females and 2 males.

To identify and characterize Mc, two approaches were employed. When family members were available, a non-shared polymorphism of the putative Mc source was identified and DNA extracted from lung tissue interrogated for the specific polymorphism by quantitative-polymerase chain reaction (qPCR).  When the Mc source was sex mismatched, fluorescence in situ hybridization (FISH) was employed with X- and Y-chromosome specific probes. Concomitant immunohistochemistry (IHC) was added for CD31, CD45, cytokeratin and SMA-α to determine cell phenotype. Cells with two distinct signals within one nucleus were counted and analyzed under bright field for IHC staining.

Results: Molecular studies indicated multiple Mc sources are detected in SSc lung, i.e. maternal, fetal and possibly sibling Mc.  By polymorphism specific qPCR concentrations ranged from 1 to 144 microchimeric cell equivalents per 105 cell tested.  By FISH 3/3 male lungs had female cells (mean: 9.3/2000, range 3-19) and 4/5 female lungs had male cells (mean: 5.8/2000, range 1-13).  Among controls, 3/4 had Mc (mean: 5/2000, range 1-8).  Interestingly, in male SSc patients, half or more of maternal Mc was positive for the endothelial cell marker CD31. 10% were positive for SMA-α.  In females, 36% of the male Mc was positive for CD31, 9.5% for SMA-α and 3.5% for cytokeratin. No microchimeric cell was positive for CD45. 

Conclusion:

These results indicate SSc lung contains Mc from multiple different sources. Microchimeric cells in the lung were not hematopoietic. The most common phenotype was endothelial, of potential additional interest in light of early endothelial cell injury in SSc. While other studies are needed, these results, along with other literature, 1 indicate that Mc can adopt different cell phenotypes so that loss of tolerance to our natural immigrants could contribute to an “auto” immune disease.

Acknowledgements: This work was supported by a grant from the Scleroderma Foundation.

1 Reviewed in: Nelson JL. The Otherness of Self: Microchimerism in health and disease.  Trends in Immunol  33(8):421-7, 2012.


Disclosure: C. GENTIL, None; J. Randolph-Habecker, None; D. K. Madtes, None; M. FANG, None; H. S. Gammill, None; C. L. Fligner, None; M. A. Houghton, None; J. L. Nelson, None.

To cite this abstract in AMA style:

GENTIL C, Randolph-Habecker J, Madtes DK, FANG M, Gammill HS, Fligner CL, Houghton MA, Nelson JL. Microchimerism Is Present in Systemic Sclerosis Lung and Includes CD31-Positive Cells [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/microchimerism-is-present-in-systemic-sclerosis-lung-and-includes-cd31-positive-cells/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/microchimerism-is-present-in-systemic-sclerosis-lung-and-includes-cd31-positive-cells/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology